Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00511017 · ClinicalTrials.gov registry record · Phase 1
Doxercalciferol in Recurrent Pediatric Solid Tumors
A Phase 1 study, sponsored by M.D. Anderson Cancer Center.
- Terminated
- Registry status
- Phase 1
- Development phase
- 1
- Enrollment target
NCT00511017: Clinical Trial Phase 1 study, sponsored by M.D. Anderson Cancer Center.
NCT00511017 is a Phase 1 study that was terminated before completion, run by M.D. Anderson Cancer Center. The registered enrollment target is 1 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00511017, a Phase 1 study, was terminated before completion, sponsored by M.D. Anderson Cancer Center.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 1 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to find the highest tolerable dose of doxercalciferol that can be given to pediatric patients with relapsed solid tumors. The safety of this drug will also be studied. Another goal is to measure the effect of the study drug on the blood levels of calcium and vitamin D.
Interventions
- DRUG Doxercalciferol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2007-08 |
| Est. Completion | 2010-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00511017
The ClinicalTrials.gov registry entry for NCT00511017 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Doxercalciferol is the first listed.
NCT00511017 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00511017 about?
NCT00511017 is a clinical study titled "Doxercalciferol in Recurrent Pediatric Solid Tumors". The goal of this clinical research study is to find the highest tolerable dose of doxercalciferol that can be given to pediatric patients with relapsed solid tumors. The safety of this drug will also be studied. Another goal is to measure the effect of the study drug on the blood levels of calcium a...
What is the current status of trial NCT00511017?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 1 participants. The study started on 2007-08. Estimated completion is 2010-09.
What interventions are being tested in trial NCT00511017?
The interventions under investigation include: Doxercalciferol (DRUG).
Who is sponsoring clinical trial NCT00511017?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.